The aim of the research collaboration is to reveal the mechanism of action and pharmacological characterization of a drug candidate.
Under the terms of the collaboration, Salipro Biotech will utilize its expertise in stabilizing challenging membrane proteins such as GPCRs, ion channels and transporters via its Salipro technology platform to advance a Sumitomo Pharma’s drug discovery program by characterizing a drug candidate with the desired therapeutic properties against a selected target.
“We are excited to be working with Sumitomo Pharma to investigate this drug candidate and its mechanism of action,” says Jens Frauenfeld, CEO of Salipro Biotech. “Our distinct expertise and proprietary technology platform unlock novel drug targets that were previously considered too challenging to identify. By combining our expertise with Sumitomo Pharma’s advanced capabilities in CNS drug discovery and development, we aim to shed light on the therapeutic potential of a drug candidate.”
Photo of Jens Frauenfeld: Salipro
